This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, Vladimir,
Salloway, Stephen,
van Dyck, Christopher H.,
Dubois, Bruno,
Andreasen, Niels,
Brody, Mark,
Curtis, Craig,
Soininen, Hilkka,
Thein, Stephen,
Shiovitz, Thomas,
Pilcher, Gary,
Ferris, Steven,
Colby, Susan,
Kerselaers, Wendy,
Dockens, Randy,
Soares, Holly,
Kaplita, Stephen,
Luo, Feng,
Pachai, Chahin,
Bracoud, Luc,
Mintun, Mark,
Grill, Joshua D.,
Marek, Ken,
Seibyl, John,
Cedarbaum, Jesse M.,
Albright, Charles,
Feldman, Howard H.,
Berman, Robert M.
Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]
Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study
Mild cognitive impairment (MCI) in Parkinson’s disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal […]
A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an Open-Label Extension
Remington, Ruth,
Lortie, Jevin J.,
Hoffmann, Heather,
Page, Robert,
Morrell, Christopher,
Shea, Thomas B.
Thirty-four individuals with mild cognitive impairment were randomized for 6 months to a nutraceutical formulation (NF: folate, alpha-tocopherol, B12, S-adenosyl methioinine, N-acetyl cysteine, acetyl-L-carnitine) or indistinguishable placebo, followed by a 6-month open-label extension in which all individuals received NF. The NF cohort improved in the Dementia Rating Scale (DRS; effect size >0.7) and maintained baseline […]
Family oversight and the quality of nursing home care for residents with advanced dementia
Background: The quality of nursing home (NH) care for residents with advanced dementia has been described as suboptimal. One relatively understudied factor in the provision of NH care is the role of private oversight and monitoring by family members and friends. Objective: To examine the association between private oversight and the quality of end-of-life care […]
Longitudinal medication usage in Alzheimer disease patients
Zhu, Carolyn W.,
Livote, Elayne E.,
Kahle-Wrobleski, Kristin,
Scarmeas, Nikolaos,
Albert, Marilyn,
Brandt, Jason,
Blacker, Deborah,
Sano, Mary,
Stern, Yaakov
This study examined in detail patterns of cholinesterase inhibitors (ChEIs) and memantine use and explored the relationship between patient characteristics and such use. Patients with probable Alzheimer disease AD (n=201) were recruited from the Predictors Study in 3 academic AD centers and followed from early disease stages for up to 6 years. Random effects logistic […]
Estimation and validation of a multiattribute model of Alzheimer disease progression
Stallard, Eric,
Kinosian, Bruce,
Zbrozek, Arthur S.,
Yashin, Anatoliy I.,
Glick, Henry A.,
Stern, Yaakov
Objectives: To estimate and validate a multiattribute model of the clinical course of Alzheimer disease (AD) from mild AD to death in a high-quality prospective cohort study, and to estimate the impact of hypothetical modifications to AD progression rates on costs associated with Medicare and Medicaid services. Data and Methods: The authors estimated sex-specific longitudinal […]
Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items
Schmitt, Frederick A.,
Aarsland, Dag,
Brønnick, Kolbjørn S.,
Meng, Xiangyi,
Tekin, Sibel,
Olin, Jason T.
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for […]
Reducing dangerous nighttime events in persons with dementia by using a nighttime monitoring system
Rowe, Meredeth A.,
Kelly, Annette,
Horne, Claydell,
Lane, Steve,
Campbell, Judy,
Lehman, Brandy,
Phipps, Chad,
Keller, Meredith,
Pe Benito, Andrea
Background: Nighttime activity, a common occurrence in persons with dementia, increases the risk for injury and unattended home exits and impairs the sleep patterns of caregivers. Technology is needed that will alert caregivers of nighttime activity in persons with dementia to help prevent injuries and unattended exits. Methods: As part of a product development grant, […]
A serum protein-based algorithm for the detection of Alzheimer disease
O'Bryant, Sid E.,
Xiao, Guanghua,
Barber, Robert,
Reisch, Joan,
Doody, Rachelle,
Fairchild, Thomas,
Adams, Perrie,
Waring, Steven,
Diaz-Arrastia, Ramon
Objective: To develop an algorithm that separates patients with Alzheimer disease (AD) from controls. Design: Longitudinal case-control study. Setting: The Texas Alzheimer’s Research Consortium project. Patients: We analyzed serum protein-based multiplex biomarker data from 197 patients diagnosed with AD and 203 controls. Main Outcome Measure: The total sample was randomized equally into training and test […]